Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.96
-0.3796-1.14%
Post-market: 33.050.0854+0.26%16:10 EDT
Volume:1K
Turnover:46.07K
Market Cap:42.03M
PE:- -
High:33.17
Open:33.17
Low:32.95
Close:33.34
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.18
T/O Rate:0.11%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

GenScript Unit Legend Biotech to Present Updated Long-Term Carvykti Cartitude-2 Data at IMS Meeting

Reuters
·
Sep 10

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live
·
Sep 10

Ascendis Pharma SVP & PAO Mads Bodenhoff Disposes of 3,000 Common Shares Worth $810,570

Reuters
·
Sep 10

Ascendis Pharma announces data from reACHin Trial

TIPRANKS
·
Sep 10

Rhythm Pharmaceuticals Highlights Imcivree Launch Progress in Acquired Hypothalamic Obesity Presentation

Reuters
·
Sep 09

Atai Beckley Holds Shareholder Meeting, Quorum Met with 65.6% Shares Represented

Reuters
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Sep 09

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Sep 09

Structure weakness ‘disconnected’ from underlying data, says Jefferies

TIPRANKS
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Sep 09

Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback

TIPRANKS
·
Sep 09

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Sep 09

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS
·
Sep 09

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08

Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026

Reuters
·
Sep 08

AlzeCure Pharma to Present at Aktiedagen Event in Stockholm

Reuters
·
Sep 08